When did Jupiter Neurosciences IPO?

Jupiter Neurosciences (JUNS) raised $11 million in an IPO on Tuesday, October 1st 2024. The company issued 2,800,000 shares at $4.00 per share. Dominari Securities and Revere Securities acted as the underwriters for the IPO.

Notice: This company recently went public with an IPO on Tuesday, October 1st 2024. They issued 2,800,000 shares at $4.00 per share. We will continue to update data for JUNS as it becomes available.

NASDAQ:JUNS

Jupiter Neurosciences (JUNS) Stock Price, News & Analysis

Compare

About Jupiter Neurosciences Stock (NASDAQ:JUNS)

Advanced Chart

Ad Porter & Company

Elon knows the truth, which is why they want him silenced

Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.

Watch this new documentary and you’ll discover what Elon knows,

Get Jupiter Neurosciences alerts:

Key Stats

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A
Volume: N/A
Average Volume: N/A
Market Capitalization: N/A
P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A
Consensus Rating: N/A

Company Overview

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

JUNS Stock News Headlines

Fact check: False claim 'Star of Bethlehem' will shine for first time since 1226 on Dec. 21

December 21, 2023 | usatoday.com

Why We Lie, And The Neuroscience Behind It

October 8, 2023 | forbes.com

Elon knows the truth, which is why they want him silenced

October 8, 2024 | Porter & Company (Ad)

How do you attack brain cancer? A world-class lab in Jupiter is trying something innovative.

July 29, 2023 | msn.com

Neuroscience Explains Why You Need To Write Down Your Goals If You Actually Want To Achieve Them

April 23, 2023 | forbes.com

Jupiter Neurosciences, Inc. Announces Research Breakthrough with JOTROL™ in Parkinson's Disease

March 1, 2023 | morningstar.com

Watch Venus and Jupiter Close In on a Glorious Conjunction

February 23, 2023 | cnet.com

FAU STILES-NICHOLSON BRAIN INSTITUTE OPENS HERALDING A NEW ERA IN NEUROSCIENCE AND EDUCATION

January 22, 2023 | finance.yahoo.com

See More Headlines

JUNS Stock Analysis - Frequently Asked Questions

: Jupiter Neurosciences (JUNS) raised $11 million in an IPO on Tuesday, October 1st 2024. The company issued 2,800,000 shares at $4.00 per share. Dominari Securities and Revere Securities acted as the underwriters for the IPO.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:JUNS
CUSIP: N/A
CIK: 1679628
Web: www.jupiterorphan.com
Phone: 561 406 6154
Fax: N/A
Employees: 5
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NASDAQ:JUNS) was last updated on 10/8/2024 by MarketBeat.com Staff

From Our Partners